🧠 This Week in Neuroscience: Pediatric Migraine Breakthrough, First MS CAR T-Cell Therapy, Gene Therapy Milestones, and More
Explore the latest developments shaping neuroscience, neurology, and rare CNS disease research. This week’s update spans the first CGRP antagonist approved for pediatric migraine prevention, the world’s first donor-derived CAR T-cell therapy in multiple sclerosis, advances in neuroprotective drug development, and major progress in late-stage gene therapy programs. Plus, a landmark approval for aggressive brain tumors, improved access to rare neurological disorder treatments in Canada, and promising preclinical results in schizophrenia.
📌 What’s Inside This Week’s Update
💉 FDA approves AJOVY for pediatric episodic migraine prevention
🧬 First MS patient receives donor-derived CAR T-cell therapy
🧪 Lucid-MS clears Phase 1 safety trial in multiple sclerosis
📊 Immunic fully enrolls Phase 3 trials for Vidofludimus Calcium in MS
🧠 FDA approves first systemic therapy for H3 K27M-mutant brain tumor
🇨🇦 Ultomiris gains Canadian access deal for NMOSD and gMG
🧬 REGENXBIO advances multiple late-stage gene therapy programs
🧩 Evenamide shows preclinical efficacy across schizophrenia symptoms
🧓 Jupiter launches Nugevia MND cognitive health supplement
From regulatory wins to cutting-edge therapies, this week’s roundup highlights the breakthroughs advancing neuroscience research and patient care.
📢 Stay Ahead in Neuroscience Research!
✅ Like, share, and subscribe for weekly updates on neuroscience and neurodegenerative breakthroughs
#Neuroscience #MultipleSclerosis #Migraine #GeneTherapy #BrainTumor #MyastheniaGravis #SchizophreniaResearch #RareDiseases #NeuroUpdates #LucidQuest #ClinicalTrials #FDAupdates #BiotechNews #HealthcareInnovation